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Background: Chemotherapy-induced peripheral neuropathy (CIPN) is the main dose-limiting side effect of
neurotoxic chemotherapeutic agents. CIPN can lead not only to loss of physical function, difficulties in activities of
daily living (ADLs), and decreased quality of life, but also to dose reduction, delay or even cessation of treatment.
Currently, there are few proven effective treatments for CIPN. This randomized controlled clinical trial is designed to
evaluate the effects and safety of electroacupuncture (EA) for patients with CIPN.
Methods/design: This is a multicenter, two-armed, parallel-design, patient-assessor-blinded, randomized,
sham-controlled clinical trial. Forty eligible patients with CIPN will be randomized in a ratio of 1:1 to the EA or
sham EA arms. During the treatment phase, patients will undergo eight sessions of verum EA or sham EA twice
weekly for four weeks, and then will be followed-up for eight weeks. Electrical stimulation in the EA group will
consist of a mixed frequency of 2/120 Hz and 80% of bearable intensity. Sham EA will be applied to non-acupoints,
with shallow needle insertion and no current. All outcomes and analyses of results will be assessed by researchers
blinded to treatment allocation. The effects of EA on CIPN will be evaluated according to both subjective and
objective outcome measures. The primary outcome measure will be the European Organization for Research and
Treatment of Cancer (EORTC) quality of life questionnaire to assess CIPN (QLQ-CIPN20). The secondary outcome
measures will be the results on the numerical rating scale, the Semmes-Weinstein monofilament test, the nerve
conduction study, and the EORTC QLQ-C30, as well as the patient’s global impression of change and adverse
events. Safety will be assessed at each visit.
Discussion: The results of this on-going study will provide clinical evidence for the effects and safety of EA for
CIPN compared with sham EA.
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Chemotherapy-induced peripheral neuropathy (CIPN)
is defined as damage to the peripheral nervous system
induced by neurotoxic chemotherapeutic agents, including
platinum compounds such as oxaliplatin and cisplatin,
taxanes such as paclitaxel and docetaxel, and vinca
alkaloids like vincristine [1,2]. Although the symptoms
of CIPN vary according to the type and severity of the
motor, sensory, and autonomic nerves that are affected,
most symptoms of CIPN are sensory and include numb-
ness, tingling, and shooting and burning pains in the
toes and fingers, progressing proximally in a typical
‘glove and stocking’ distribution. Furthermore, CIPN in
most patients is only partially reversible and can persist
long after treatment is terminated [3]. CIPN is one of the
major dose-limiting side effects of chemotherapy and can
lead not only to loss of physical function, difficulties in
activities of daily living (ADLs), and decreased quality
of life (QOL), but also to dose reduction or delay or
even cessation of treatment [4,5].
Dose and treatment schedule modifications of neuro-
toxic chemotherapy are currently the primary methods
used for the non-pharmacological management of CIPN
[3]. Alternative dosing regimens and treatment modifica-
tion schemes have been found to be effective in reducing
the incidence and/or severity of CIPN [6,7]. These strat-
egies, however, can potentially affect tumor response
and disease progression. Several pharmacologic agents
useful in treating peripheral neuropathy caused by other
conditions such as diabetes, have been investigated as
treatment for CIPN; these include anticonvulsants such
as gabapentin and lamotrigine, and tricyclic antidepres-
sants. To date, however, no agent has proven effective in
the treatment or mitigation of CIPN [8,9], underscoring
the need for the development of novel treatments.
Acupuncture is a popular and safe treatment intervention
used to manage various conditions including peripheral
neuropathy. Electroacupuncture (EA) has been found
to be effective in treating diabetic peripheral neuropathy
[10], neuropathic pain including post-herpetic neuralgia
and post-traumatic neuropathy [11], and human immuno-
deficiency virus (HIV)-related peripheral neuropathy
[12]. Clinical trials in patients with CIPN have shown
that acupuncture/EA alleviated symptoms [13-17] and
improved nerve conduction study (NCS) results [18],
suggesting that EA may be an effective treatment for
CIPN without causing adverse effects. Most prior studies,
however, were case reports, case series, or clinical trials
lacking a control group, resulting in a high risk of bias.
A recent Cochrane Review on acupuncture for cancer
pain included three randomized controlled trials (RCTs),
only one of which was of high methodological quality
[19]. In addition, few RCTs have evaluated EA for
CIPN, underscoring the need for well-designed robustclinical trials to provide evidence for EA in treating
CIPN.
Aim of the study
The aim of this study is to test the feasibility of a RCT
to investigate effectiveness and safety of EA, compared
with sham EA, in the treatment of CIPN. We will evaluate
whether EA improves symptoms and functioning, cutane-
ous sensation, nerve conduction, and QOL. All adverse
events will also be assessed.
The results of this study will provide evidence for the
feasibility of this clinical trial design and also yield data
to determine the appropriate sample size for future large-
scale RCTs of EA in cancer patients with neuropathy.
Methods/design
Study design and ethics
This is a patient-assessor-blinded, randomized, sham-
controlled clinical trial with two parallel arms. The trial
will be conducted at two clinical research centers in
Korea; Kyung Hee University Hospital at Gangdong and
Dongguk University Ilsan Oriental Hospital, in accord-
ance with the Declaration of Helsinki and the Guidelines
for Good Clinical Practice. This research protocol has
been reviewed and approved by the institutional review
boards (IRB) of each trial center (KHNMC-OH-IRB
2012-007 and 2012-01). Written informed consent will be
obtained from all study participants prior to enrollment.
Eligible participants will be randomized in a ratio of 1:1
to the EA or sham EA arm and receive treatment for
four weeks. Patients will be followed-up for two months
thereafter (Figure 1). Participants will be evaluated and
results will be analyzed by professionals blinded to group
allocation. This protocol has been registered with the
‘Clinical Research Information Service’ of the Republic
of Korea, a registry in the WHO Registry Network.
Participants
Inclusion criteria
Patients will be eligible if they are aged 18 years or older,
have received or are currently receiving neurotoxic chemo-
therapy, have experienced symptoms of chemotherapy-
induced peripheral neuropathy for ≥ one month, and
have scores ≥ 4 on 10 on the numerical rating scale
(NRS). Eligibility criteria will also include no use of
medication to prevent or treat neuropathy for two weeks
before screening or stability of medication to prevent
or treat neuropathy for two months before screening;
an Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) of 0 to 2; life expectancy of ≥ six
months; and provision of written informed consent.
Stable medication is defined as no change in the type
and dose of medication to prevent or treat neuropathy
for > two months before enrollment. Patients receiving
Figure 1 Flowchart showing the steps in patient recruitment, treatment, and analysis.
Kim et al. Trials 2013, 14:254 Page 3 of 7
http://www.trialsjournal.com/content/14/1/254any of those drugs will have to remain on the same med-
ications and doses throughout the study period. Patients
requiring a change in the type and dosage of medication
will be withdrawn from the study.
Exclusion criteria
Exclusion criteria are pre-existing peripheral neuropathy
or a history of peripheral neuropathy due to any cause
other than chemotherapy (for example, diabetes, peripheral
vascular disease, HIV, alcohol, toxins, hereditary factors
and nerve compression injuries); known hypersensitivity
to acupuncture or inability to cooperate with the acu-
puncture procedure; treatment with traditional Korean
medical protocols, including acupuncture, moxibustion,
cupping or herbal medicine, for peripheral neuropathy
during one month before enrollment; cardiovascular
disorder including arrhythmia or use of a pacemaker;
pregnancy or potential pregnancy and nursing; and un-
willingness to comply with this study protocol.
Randomization and allocation concealment
A total of 40 participants who meet the eligibility criteria
will be randomised in a ratio of 1:1 to the EA or sham
EA group. In this trial, constant exposure to neurotoxic
agents and concomitant use of neuropathy medications
during the study are variables that present potential
confounding effects for the study results. Therefore, this
randomization will be stratified according to the receipt of
on-going chemotherapy during enrollment or completionof therapy and according to the use of medication for
neuropathy. Patients will be randomized using a com-
puter-generated random allocation sequence through the
stratified block randomization method of SAS version
9.1.3 (SAS Institute Inc., Cary, NC, USA) by a statistician
(MHL) with no clinical involvement in this trial. Sequen-
tially numbered opaque sealed envelopes containing the
randomization assignments will be delivered to the clinical
trial center. Allocation concealment will not be broken
until the final data analysis report is completed.
Blinding
In this acupuncture research, it is not feasible to conceal
allocation from the practitioners, and the practitioners
will be aware of the allocation of each patient. However,
treatment and assessment will be performed independ-
ently, and the practitioners will not be involved in assessing
treatment outcomes. The subjects, the outcome assessors,
and the statistician performing the data analyses will be
blinded to treatment allocation throughout the study.




EA will be administered twice weekly for four weeks.
Bilateral LI4, TE3, GV39, GV41, SP6, LR3, Ba Feng,
and Ba Xie will be used for acupuncture treatment.
The acupuncture points were selected by the consensus
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searchers who specialize in traditional Korean medicine,
on the basis of a literature review [13,14,16-18] and a text-
book [20].
Single-use, sterile, filiform acupuncture needles, 0.25
mm in diameter and 40 mm in length (Dongbang Co.,
Seoul, Korea), will be inserted and stimulated manually,
but no specific de qi sensation will be provoked because
the sensitivity of acupuncture points may vary, especially
in patients with chemotherapy-induced peripheral neur-
opathy. A battery-operated EA device (PG-306 pulse
generator, Suzuki Iryoki, Tokyo, Japan) will be connected
to the bodies of needles at the acupuncture points.
Electrical stimulation will be delivered for 30 minutes
at alternating frequencies of 2 and 120 Hz, at an intensity
of 80% of each patient’s maximum tolerance.Sham electroacupuncture group
Participants allocated to the sham EA group will receive
the sham EA treatment twice weekly for four weeks.
The total number of visits and acupuncture needles will
be identical to those of the verum EA group. The selected
sham points are as follows: bilaterally at one point at the
middle of the biceps brachii muscle belly and one point at
2 cm vertically below the middle, one point at the middle
of the brachioradialis muscle belly and points at 1.5 cm, 3
cm, and 4.5 cm vertically below the middle, four points
above the upper part of the patella, one point at the upper
third above the medial part of the tibia and points at 1.5
cm, 3 cm, and 4.5 cm vertically below the upper third.
The same type of needles will be shallowly inserted
into the sham points with no manipulation for de qi and
will be connected to a deactivated EA device. No current
will be applied but the apparatus will emit the same
beeping sound and flashing light continuously for 30
minutes. Sham treatment will be performed by the same
doctors who perform the verum treatment.Education of practitioners
All EA and sham EA treatments will be performed by
doctors of Korean medicine who have been certified by
the Korean Ministry of Health and Welfare, have at least
three years of clinical experience, and have received
more than six years of college education in Korean
medicine. Each doctor will take a pre-trial training
course for this clinical research. The lead doctor specializ-
ing in acupuncture will train all other practitioners and
observe their technique periodically to ensure standard-
ization among practitioners. In addition, all study proto-
cols and details, including the recording method for the
case report form, outcome assessment methods, and
monitoring process, will be standardized between the
two centers through workshops.Prohibited concomitant treatments
In both groups, all additional treatments for peripheral
neuropathy, including drugs, supplements, and alternative
treatments, will be prohibited during the study period.
Outcome assessment
Primary outcome measurement
The primary outcome measure is the European Organi-
zation for Research and Treatment of Cancer (EORTC)
quality of life questionnaire to assess CIPN (QLQ-CIPN20),
a 20-item CIPN-specific questionnaire developed to evalu-
ate patients’ experience of symptoms and functional limita-
tions related to CIPN. The EORTC QLQ-CIPN20 includes
three subscales assessing sensory, motor, and autonomic
symptoms, with each item measured on a 1 to 4 Likert
scale (1, not at all; 4, very much). This questionnaire
has been assessed in patients with cancer, who were
receiving various chemotherapy regimens, and has been
shown to have reliable internal consistency [21].
Secondary outcome measurements
CIPN symptom intensity will be assessed using a numer-
ical rating scale (NRS), the clinical tool most commonly
used to help patients communicate the intensity of their
symptoms. This method has been validated in cancer
patients [22,23]. Subjects will be asked to rate their average
neuropathic symptoms, including numbness, tingling, and
pain, on an 11-point scale (0 = no symptoms; 10 = worst
possible symptoms).
The Semmes-Weinstein monofilament (SWM) test will
be used to evaluate light touch sensation. The SWM
examination is a non-invasive, cost-effective, and objective
quantitative sensory test often used in research and
clinical practice. A full set of 20 SWM from 1.65- to
6.65-gauge (North Coast Medical, Inc., Morgan Hill,
CA, USA) will be used in this trial. This test has been
found effective in assessing peripheral neuropathy in
cancer patients [24].
The EORTC QLQ-C30 will be used to evaluate health-
related QOL (HRQOL) in patients with cancer. The
EORTC QLQ-C30 is a 30-item questionnaire assessing
five functional scales (physical, role, cognitive, emotional,
and social), three symptom scales (fatigue, pain, nausea,
and vomiting), and other symptoms and problems fre-
quently encountered in cancer patients (dyspnea, appetite
loss, insomnia, constipation, diarrhea, and financial diffi-
culties). Its validity and reliability have been demonstrated
[25,26].
NCS is a non-invasive, objective, and reproducible
measurement of neurologic function in peripheral neur-
opathy. Motor conduction will be examined in median
and tibial nerves by measuring onset latency, the ampli-
tude of compound muscle action potential and motor
conduction velocity. Sensory conduction will be tested
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tency, the amplitude of sensory nerve action potentials,
and sensory conduction velocity. NCS will be performed
using the Medelec Synergy system (Oxford Instruments,
Abingdon, UK) in an air-conditioned room at constant
temperature at Dongguk University Ilsan Oriental Hos-
pital only.
Patient Global Impression of Change (PGIC) is a seven-
point categorical scale in which patients rate their overall
change in symptoms since the beginning of the study (1 =
very much improved, 2 =much improved, 3 =minimally
improved, 4 = no change, 5 =minimally worse, 6 =much
worse, 7 = very much worse). PGIC has been used in many
clinical trials in cancer patients and is recommended to
define minimal clinically important differences [8,9,27].
The schedule of procedures and evaluations is presented
in Table 1.
Sample size
Although several studies have investigated the effects of
acupuncture on cancer and related symptoms, few RCTs
have assessed the effects of EA on CIPN. There is no
previous study on which to base the sample size calcula-
tion. Therefore, this pilot study will evaluate the efficacy
and safety of EA and the feasibility of clinical trials. The
findings will also provide data about the variability of
the primary and secondary outcomes, thereby facilitating
the performance of power calculations for full-scale RCTs.
Taking into account the minimum number of subjects
necessary to assess the effects of EA, we calculated a total
sample size of 40 patients, 20 in each group [28,29].
Data analysis
The clinical effects of EA on CIPN will be analyzed on
an intent-to-treat (ITT) basis. Missing values will beTable 1 Schedule for treatment and outcome
measurement
Period B T F
Week 1 2 3 4 8 12
Informed consent x
Demographic characteristics x
EA/Sham EA treatment x x x x x x x x
EORTC QLQ-CIPN20 x x x x x
NRS x x x x x x x x x x x
SWM test x x x x x
NCS x x
EORTC QLQ-C30 x x x x x
PGIC x x x
Safety assessment x x x x x x x x x x
B: baseline, EA: electroacupuncture, F: follow-up phase, NCS: nerve conduction
study NRS: numerical rating scale, SWM: Semmes-Weinstein monofilament,
PGIC: patient global impression of change. T: treatment phase.imputed by the last observation carried forward method.
The results of the ITT analysis will be compared with those
of per-protocol (PP) analysis to evaluate the sensitivity.
Baseline demographic and clinical characteristics of
patients will be reported as mean (standard deviation
or 95% confidence intervals) or as maximum or minimum
for continuous variables, and as frequencies and percent-
ages for categorical variables. Continuous variables will
be analyzed by two-sample t-tests or Wilcoxon rank
sum tests, and categorical variables will be analyzed
using the chi-squared or Fisher’s exact test, according
to whether or not the data are normally distributed.
Between group differences in primary and secondary
outcomes will be analyzed by analysis of covariance, with
the baseline score and centers as the covariates and
current use of chemotherapy or neuropathy medication
as stratified variables, at the second, fourth (primary
endpoint), eighth and twelfth weeks. The results for the
stratified groups will be compared with the results for
the whole subject pool (non-stratified) to determine
whether current use of chemotherapy or neuropathy
medication is a suitable stratification factor that affects
the treatment outcome. Mean differences from baseline
to post-treatment in each group will be assessed using
paired t-tests or Wilcoxon signed rank tests. Repeated
measures analysis of variance will be used for assessments
at different time points. All statistical analyses will be
performed using SAS version 9.1.3 (SAS institute Inc.,
Cary, NC, USA) by a statistician blinded to patient alloca-
tion, and a significance level of 0.05 will be used.
Safety and monitoring
All adverse events will be observed and reported by
patients and researchers during each patient visit. Any
expected or unexpected adverse events related to this
study will be recorded and monitored until its resolution.
Safety will also be assessed by performing blood tests,
including complete blood count, differential count, and
renal and liver function tests, at the screening visit and
after the end of treatment. In addition, at each visit,
vital signs will be measured, and adverse events will be
recorded.
Data and safety monitoring will be conducted at peri-
odic intervals during the study. The monitors will check
study protocol compliance and informed consent docu-
ments and evaluate the progress of the trial, including
participant recruitment, data quality and timeliness, and
performance of the intervention at each trial site.
Discussion
The increased incidence of cancer has been accompanied
by an increase in the number of patients receiving various
types of chemotherapy. Although these treatments have
enhanced survival rates, they have also increased side
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common and devastating chemotherapy-associated side
effect, frequently cited by patients as having a substantial
impact on ADLs and QOL [30]. Symptoms of CIPN mani-
fest differently in patients, with diagnoses and assessments
primarily dependent on subjective reporting by patients.
Therefore, use of appropriate objective outcome measure-
ments, in addition to specific assessments of subjective
symptoms, is crucial.
In the present study, to reflect subjectively reported
symptoms, we will use the EORTC QLQ-CIPN20 as the
primary study outcome to comprehensively assess symp-
toms of the sensory, motor, and autonomic nervous sys-
tems, with the NRS also used as a secondary outcome.
In addition to subjective assessments by the patients, the
SWM test will be used to evaluate light touch threshold as
an objective assessment tool for peripheral neuropathy,
quantitatively assessing sensory functions. The NCS is
also considered an important objective and quantitative
parameter of peripheral nerve function and has been
used in many trials of peripheral neuropathy. Acupuncture
treatment for CIPN has been reported to improve NCS
results [18] as well as peripheral neuropathy of undefined
etiology [31] and diabetic neuropathy [32], although these
trials were non-randomized, non-blinded, or included
patients with peripheral neuropathy caused by other
diseases. We have therefore designed an RCT to investi-
gate whether EA has a significant effect on NCS results
in patients with CIPN.
This pilot patient-assessor-blinded RCT will investigate
the efficacy and safety of EA for CIPN, assess the feasibil-
ity and relevance of the intervention and the study design,
and provide a clinical foundation for future large-scale,
multicenter clinical trials.
Trial status
This trial is currently recruiting participants.
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